The expansion of the global artificial insemination market is linked to the rising incidence of infertility on a global scale, spurred by shifting lifestyles. Contributing to this growth are factors such as evolving regulatory frameworks surrounding artificial insemination and technological advancements in the field. The surge in fertility-related disorders stands out as a significant driver propelling the artificial insemination market forward, as infertility emerges as a prevalent health concern affecting both men and women.
Infertility has become a pervasive health issue, affecting a substantial portion of the global population. The prevalence of fertility-related disorders has increased, necessitating effective and advanced reproductive solutions. In this context, artificial insemination has gained prominence as a viable method to address fertility challenges.
One of the key drivers of the artificial insemination market is the changing lifestyle patterns witnessed globally. Modern lifestyles have introduced various factors that contribute to infertility, affecting both men and women. These lifestyle changes encompass aspects such as increased stress levels, elevated consumption of alcohol, and a rise in smoking habits. Such lifestyle choices have been identified as significant contributors to infertility-related concerns, thereby propelling the demand for artificial insemination solutions.
Moreover, the evolving regulatory landscape surrounding artificial insemination has played a crucial role in fostering market growth. Regulatory bodies have recognized the importance of regulating and standardizing practices in the field of assisted reproductive technologies, including artificial insemination. This regulatory clarity not only ensures the safety and efficacy of procedures but also instills confidence in both healthcare providers and individuals seeking fertility treatments.
Technological advancements in artificial insemination techniques have further fueled market growth. Continuous innovations and improvements in the field have enhanced the success rates of artificial insemination procedures. Advanced technologies enable healthcare professionals to offer more precise, efficient, and successful artificial insemination services, contributing to the overall growth of the market.
The artificial insemination market is positioned at the intersection of addressing infertility challenges and advancing reproductive technologies. The increasing prevalence of fertility-related disorders emphasizes the importance of accessible and effective solutions, making artificial insemination a critical component of contemporary reproductive healthcare.
In conclusion, the global artificial insemination market is witnessing robust growth driven by factors such as the growing rate of infertility, changing lifestyles, evolving regulatory frameworks, and technological advancements. As infertility becomes a widespread health concern, the demand for advanced reproductive solutions like artificial insemination continues to rise, emphasizing the pivotal role this market plays in addressing contemporary fertility challenges.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2023 | USD 26.62billion Billion |
Growth Rate | 9.8% (2023-2032) |
The assisted reproductive technology market size was valued at USD 26.62 billion in 2023 and is projected to grow from USD 29.22 Billion in 2024 to USD 38.8 billion by 2032, exhibitinga compound annual growth rate (CAGR) of 3.60% during the forecast period (2024 - 2032). Over the forecast period, the rise in infertility cases worldwide are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
December 2023: Non-Resident Indian (NRI) patients in India are increasingly seeking IVF procedures because to the favorable mix of high success rates and affordable costs. India's superior assisted reproductive technology produces remarkable results, with more than 45,000 IVF rounds performed every year, demonstrating a significant rate of success. The cost-effectiveness of in vitro fertilization (IVF) in India is a crucial consideration. While the average cost of a single IVF cycle in the USA is over USD 12,500, in India, the cost ranges from approximately USD 1,500 to USD 4,500, excluding any additional procedures. Moreover, the nation's progress in assisted reproductive technology (ART) guarantees that individuals have the opportunity to utilize the most up-to-date fertility therapies. India's favorable position as a destination for fertility treatments among NRIs is due to the significant difference in pricing and the provision of high-quality medical care. Little Angel IVF has just introduced top-notch fertility therapies that combine skilled medical expertise with innovative reproductive technologies specifically designed for NRI patients.
In November 2023, Ovia Health by Labcorp announced the debut of a new fertility and family-building benefit for businesses and health plans. Ovia Health, a digital family health benefits firm, was bought by Labcorp, a laboratory services company, in 2021. Ovia Health collaborates with payers and employers. The organization, situated in Boston, offers a variety of services including tracking menstrual cycles, providing support for family-building, and offering assistance during menopause. The Ovia Health app provides users with the ability to obtain immediate health coaching, a customized care plan, and individualized assistance from specialists in family health. Starting in January, organizations and health plans can offer a personalized fertility and family building benefit to their employees and members. This encompasses the Ovia Wallet, a financial instrument that enables companies to allocate funds for qualified services, such as in vitro fertilization (IVF), egg freezing, adoption, and surrogacy.
Assisted Reproductive Technology Market Trends
In-vitro fertilization (IVF) is a method that comes under the type of assisted reproductive technologies (ART). Compared to what is regarded as natural and conventional ways of conception, IVF is extremely different; following an infertility test, when the doctor tries to determine sexual behaviors and any specific causes of infertility, the treatment is frequently administered. The eggs from the ovaries are removed by the doctor, fertilized in a lab, and stored there until they develop into viable embryos. One of these embryos is then transferred back into the mother's womb. Because of the high procedure success rate and ongoing improvement, the IVF segment is anticipated to have a sizable proportion of the market under research.
The development of IVF technology, rising public awareness of and government measures to control surrogacy, and expanding IVF coverage are other essential elements that are anticipated to have a crucial impact on the development of the studied market. It showed a state-appropriate authority to control in vitro fertilization (IVF) clinics and outlaw commercial surrogacy. The Assisted Reproductive Technologies (ART) legislation, which became law in response to surrogacy's rising popularity, offered hope to infertile couples struggling with moral, ethical, and social issues. After receiving the permission of the five-member authority headed by the Special Secretary (Public Health), the IVF and ART clinics will now be registered. Therefore, IVF has enhanced theAssisted Reproductive Technologymarket CAGRacross the globe in the recent years.
However, increasing infertility in the region coupled with initiatives by public organizations that are likely to increase the growth of the Assisted Reproductive Technologymarketrevenue.
The Assisted Reproductive Technologymarket segmentation, based on Diagnosis, includes, Ovulation Testing, Hysterosalpingography. The Ovulation testing segment held the majority share in 2022 contribution to around in respect to the assisted reproductive technology market revenue. This is primarily owing to the rising prevalence of the rise in infertility cases worldwide are the key market drivers enhancing the market growth across the globe. The ovulation segment market and held the majority share in 2022 contribution to respect to the Assisted Reproductive Technology market revenue.
In 2021, Cooper Surgical introduced collaboration with Virtus Health and enhanced the developed technologies in fertility, increasing research and development and making the availability of treatment for infertile couples.
In 2021, Hamilton Thorne Ltd. developed GYNEMED GM501, which is utilized for in-vitro washing and techniques mentioned for the handling of oocytes and embryos by humans and got approval from the United States and Europe and is ready for marketing.
The Assisted Reproductive Technology market segmentation, based on the type, includes Ovulation Induction, Artificial Insemination, Surrogacy. Ovulation Induction held the majority share in 2022. Artificial insemination is anticipated to witness highest growth with a CAGR of 8.58% during the forecast period. Artificial insemination is intended for minor fertility conditions and is usually done for same-sex couples or single women. The success rate for artificial insemination varies with the age. As per the Human Fertilization and Embryology Authority (HFEA), success rates for artificial insemination per individual cycle is around 15.8% for women aged below 35 years, 11% for females aged 35 to 39 years, and 4.7% for females aged 40 to 42 years. Surrogacy has the least share in 2022 because Commercial surrogacy is completely banned in majority of countries that has stimulated the growth of altruistic as well as gestational surrogacy to some extent. Surrogacy market will witness 24% CAGR during the forecast period owing to increasing number of women suffering from fertility problems resulting in difficulty in sustaining pregnancy or getting pregnant. The fertility rate in developed countries is usually low due to lifestyle choices, easy availability of birth control measures and economic affluence.
Fig-1 Assisted Reproductive Technology Market, by Type,2022& 2030 (USD billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on End Users, the assisted reproductive technology industry has been segmented into Hospitals, Clinics, IVF Center. The Clinics end-use segment has dominated the industry in 2022 and accounted for the largest share of more than 79.93% of the total revenue. The feature is anticipated to continue to grow at the fastest rate in the leading industry position throughout the forecast period.IVF centers are anticipated to witness highest growth with a CAGR during the forecast period. The hospitals and other settings end-use segment is expected to witness lucrative growth in the low- and middle-income countries owing to insufficient infrastructure.
In June 2022, Inception Fertility expanded its ecosystem to include the launch of HavenCryo, a long-term reproductive tissue, and cryopreservation storage solution that offers a unique experience for fertility providers and patients. It provides technology for assisted reproductive technologies Industry.
In March 2022, CK Birla Healthcare launched its flagship fertility clinic, Birla Fertility, in New Delhi with Assisted Reproductive Technology.
Assisted Reproductive Technology Market Regional Outlook
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. Europe Assisted Reproductive Technology market is expected to exhibit a significant CAGR growth during the study period. This is attributed to the growing incidence Growing obesity among women, Increase in ovulation disorders, change to sedentary lifestyle, growing consumption of unhealthy diet in the population across the diet.
Further, the major countries studiedin the market reportare The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 ASSISTED REPRODUCTIVE TECHNOLOGYMARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Assisted Reproductive Technologymarketthe large percentage is ascribed to an increase in the infertility rate, more excellent knowledge of fertility treatments, technological developments, and encouraging government program. The growth is linked to the success that people undergoing the treatment are experiencing.Further, the Germany Assisted Reproductive Technologymarketheld the largest market share, and the UK Assisted Reproductive Technologymarket was the fastest growing market in the European region
The Asia-Pacific Assisted Reproductive TechnologyMarket is expected to grow at the fastest CAGR from 2022 to 2030. This is due to increased rates of infertility. Moreover, JapanAssisted Reproductive Technologymarket held the largest market share, and the IndiaAssisted Reproductive Technologymarket was the fastest growing market in the Asia-Pacific region
For instance, India assisted Reproductive Technologymarket is the favored destination for medical travelers due to the availability of advanced technology, & cost-effective treatments. On the other hand, Singapore is famous for the presence of well-trained doctors, state-of-the-art facilities, and quality care.
Assisted Reproductive Technology Market Key Players& Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the Assisted Reproductive Technologymarket, grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Assisted Reproductive Technologyindustry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Theassisted reproductive technology industry with increased developments and increase in research and development with enhanced investment from the government with advanced technologies and infrastructure in the health care sectors. Increasing disposable with improved utilization of the health care center due to infertility problems rising among women improve the growth of Assisted Reproductive Technology industry.
The Assisted Reproductive Technologymarket major player such as Cosmos Biomedical Limited, CaliforniaCryobank, Bloom IVF Centre, CryolabLtd, Parallabs, OvaScience, Anecovaare working to expand the market demand by investing in research and development activities.
Hamilton Thorne, Inc. (HTI) manufactures and markets precision laser systems, imaging systems, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. HTI’s customer base comprises fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
In 2021, Hamilton Thorne Ltd. got FDA approval in the United States and Europe for marketing the GYNEMED GM501, a ready-to-use medium developed for in vitro washing and handling procedures of human oocytes and embryos. CooperSurgical announced a partnership with Virtus Health in 2021 to strengthen its fertility technology, making advanced treatment more accessible to infertile couples.
Inception’s medical experts are leading pioneers in fertility care. Our doctors are some of the first to use breakthrough assisted reproductive technologies (ART) – including in vitro fertilization (IVF), preimplantation genetic testing (PGT) and fertility preservation services – and they continue to lead the industry by building on these technologies by through development, research and thought leadership.
In June 2022, Inception Fertility expanded its ecosystem to include the launch of HavenCryo, a long-term reproductive tissue, and cryopreservation storage solution that offers a unique experience for fertility providers and patients. It includes technology for assisted reproductive technologies (ART).
Key Companies in the Assisted Reproductive Technology market includes
Assisted Reproductive Technology Industry Developments
In 2021, Cooper Surgical introduced collaboration with Virtus Health and enhanced the developed technologies in fertility, increasing research and development and making the availability of treatment for infertile couples.
In 2021, Hamilton Thorne Ltd. developed GYNEMED GM501, which is utilized for in-vitro washing and techniques mentioned for the handling of oocytes and embryos by humans and got approval from the United States and Europe and is ready for marketing.
Assisted Reproductive Technology Regional Outlook
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)